Dr. Shoushtari on the Design of the CheckMate-067 Trial in Advanced Melanoma

Video

Alexander N. Shoushtari, MD, discusses the design of the ​phase 3 CheckMate-067 trial in advanced melanoma. 

Alexander N. Shoushtari, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses the design of the ​phase 3 CheckMate-067 trial in advanced melanoma. 

​The study randomized ​patients with previously untreated, unresectable, stage III or IV melanoma 1:1:1 to receive 1 mg/kg of nivolumab (Opdivo) plus 3 mg/kg of ipilimumab (Yervoy) for 4 doses​, followed by 3 mg/kg of nivolumab​; 3 mg/kg of nivolumab plus ipilimumab-matched placebo; or 3 mg/kg of ipilimumab for 4 doses plus nivolumab-matched placebo until progression or unacceptable toxicity, says Shoushtari.

Less common subtypes, such as mucosal ​and acral melanoma, were included in the study, ​but the majority of patients had cutaneous melanoma, ​adds Shoushtari. Notably, patients with uveal melanoma ​were excluded. 

Ultimately, the trial was powered to detect a difference in progression-free survival and overall survival between nivolumab and ipilimumab​, as well as ​between the combination of nivolumab and ipilimumab and ipilimumab monotherapy, ​Shoushtari explains.

The difference in efficacy between nivolumab monotherapy and the combination regimen, as well as the long-term outcomes of patients with mucosal melanoma served as exploratory analyses of the study, Shoushtari concludes. 

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD